What is the primary uptake site for FDG associated with hematopoietic growth factors?

The primary uptake site for fluorodeoxyglucose (FDG) associated with hematopoietic growth factors is bone marrow. FDG is a radiopharmaceutical widely used in positron emission tomography (PET) imaging due to its ability to mimic glucose metabolism. Bone marrow is a living tissue that is highly metabolically active, particularly in the context of hematopoiesis, or the formation of blood cells.

Hematopoietic growth factors stimulate the production of various types of blood cells, including red blood cells, white blood cells, and platelets, which can lead to increased FDG uptake in the bone marrow. This elevated uptake reflects the increased metabolic activity of stem and progenitor cells responding to those growth factors. As a result, when assessing areas of increased FDG uptake in patients receiving hematopoietic growth factors, the bone marrow becomes a significant area of interest, providing valuable diagnostic information about hematological health and behavior.

In contrast, other organs like the liver, spleen, and lymph nodes may exhibit FDG uptake, but their association with hematopoietic growth factors is not as direct or pronounced as in bone marrow. Thus, recognizing the primary site for FDG uptake in relation to hematopoietic activity